All living things have a fleet of tiny copy machines that turn instructions from DNA into RNA molecules responsible for helping build proteins that keep organisms alive. One of those nanoscale ...

Inside every cell, thousands of proteins must reach the right place at the right time. Helping coordinate this complex ...

CRISPR-Cas13d is increasingly used for RNA knockdowns, but off-target cleavage of near-cognate RNAs hinders its broader ...

Scientists are searching some of Earth’s oldest rocks for tiny fossils that could reveal how simple microbial life made the ...

Mature mammalian cardiomyocytes (CMs) develop compact sarcomeric structures that inhibit proliferation. Consequently, CMs must dedifferentiate to a fetus-like state, which is accompanied by sarcomere ...

Structure Therapeutics reported highly positive Phase 2 ACCESS II data for aleniglipron, achieving ~16% placebo-adjusted weight loss with strong statistical significance and no plateau. Aleniglipron’s ...

A Structure Therapeutics obesity pill helped patients lose an average of nearly 40 pounds in a mid-stage clinical trial, keeping the drug competitive in the growing crowd of oral medications pursuing ...

This article has been updated to correct the comparable weight loss and discontinuation rate for the Wegovy pill. Shares of Structure Therapeutics rallied 5.4% on Monday after the company said higher ...

Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Structure Therapeutics said Monday that its ...

Structure Therapeutics has touted the 16% weight loss—about 39 pounds—seen by aleniglipron as the best results yet for an oral GLP-1 drug, as the obesity biotech readies the candidate for phase 3. The ...

This log tiny prefab house is filled with all types of beautiful wood and even has a loft! The manufacturer for this modular house is in partners with Hilltop Structures where I toured the home. The ...

Jan 14 (Reuters) - Structure Therapeutics' (GPCR.O), opens new tab CEO expects oral weight-loss pills to capture as much as half of the GLP-1 market by 2030, driven partly by pent-up demand from ...